$574 Million is the total value of RTW INVESTMENTS, LP's 27 reported holdings in Q3 2017. The portfolio turnover from Q2 2017 to Q3 2017 was 25.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ALNY | Sell | Alnylam Pharmaceuticals Inc | $73,236,000 | -11.8% | 623,338 | -40.1% | 12.76% | -27.1% |
| PTCT | Buy | PTC Therapeutics Inc | $69,938,000 | +15.5% | 3,495,143 | +5.8% | 12.18% | -4.6% |
| BMY | Buy | Bristol Myers Squibb Co | $52,746,000 | +22.2% | 827,512 | +6.8% | 9.19% | +1.0% |
| RGNX | Buy | Regenxbio Inc | $50,710,000 | +101.7% | 1,539,005 | +20.9% | 8.83% | +66.7% |
| AVXS | Sell | Avexis Inc | $45,237,000 | -6.2% | 467,667 | -20.3% | 7.88% | -22.5% |
| LJPC | Sell | La Jolla Pharmaceutical Co | $36,321,000 | +10.2% | 1,044,307 | -5.7% | 6.33% | -9.0% |
| ACHN | Buy | Achillion Pharmaceuticals In | $35,201,000 | +382.2% | 7,839,766 | +392.9% | 6.13% | +298.3% |
| ABUS | Buy | Arbutus Biopharma Corp | $32,651,000 | +74.1% | 5,266,280 | +1.1% | 5.69% | +43.8% |
| AGEN | Sell | Agenus Inc | $18,604,000 | +11.2% | 4,218,520 | -1.4% | 3.24% | -8.1% |
| CORI | Buy | Corium Intl Inc | $18,564,000 | +52.5% | 1,675,479 | +2.7% | 3.23% | +25.9% |
| BCRX | Sell | BioCryst Pharmaceuticals | $17,421,000 | -6.0% | 3,324,705 | -0.3% | 3.03% | -22.4% |
| OXFD | Buy | Oxford Immunotec Global PLC | $17,344,000 | +21.8% | 1,032,370 | +21.9% | 3.02% | +0.6% |
| BLUE | Sell | bluebird bio Inc | $14,295,000 | +30.4% | 104,078 | -0.3% | 2.49% | +7.7% |
| OSUR | Sell | OraSure Technologies Inc | $12,053,000 | +18.7% | 535,707 | -8.9% | 2.10% | -1.9% |
| DRNA | Dicerna Pharmaceuticals Inc | $11,954,000 | +81.4% | 2,078,991 | 0.0% | 2.08% | +49.9% | |
| TCMD | Sell | Tactile Sys Technology Inc | $10,932,000 | +2.7% | 353,216 | -5.1% | 1.90% | -15.1% |
| MYOK | New | Myokardia Inc | $10,882,000 | – | 253,962 | +100.0% | 1.90% | – |
| ATRA | Sell | Atara Biotherapeutics Inc | $10,857,000 | -33.9% | 656,018 | -44.1% | 1.89% | -45.4% |
| MASI | Buy | Masimo Corp | $10,465,000 | +13.8% | 120,900 | +19.8% | 1.82% | -6.0% |
| VIVE | Buy | Viveve Med Inc | $7,719,000 | -13.3% | 1,473,028 | +18.8% | 1.34% | -28.4% |
| VRAY | Buy | Viewray Inc | $5,878,000 | +18.9% | 1,020,462 | +33.5% | 1.02% | -1.7% |
| SBPH | Sell | Spring Bk Pharmaceuticals In | $4,195,000 | +23.9% | 249,095 | -0.4% | 0.73% | +2.4% |
| BVX | New | Bovie Medical Corp | $3,852,000 | – | 1,139,600 | +100.0% | 0.67% | – |
| ZYNE | New | Zynerba Pharmaceuticals Inc | $1,672,000 | – | 200,000 | +100.0% | 0.29% | – |
| GBT | Sell | Global Blood Therapeutics In | $817,000 | +13.3% | 26,310 | -0.3% | 0.14% | -6.6% |
| ARGX | Sell | argenx SEsponsored adr | $563,000 | +6.2% | 24,906 | -0.3% | 0.10% | -12.5% |
| SRTSW | SENSUS HEATLHCARE INC*w exp 06/08/201 | $90,000 | -3.2% | 155,000 | 0.0% | 0.02% | -20.0% | |
| IVTY | Exit | Invuity Inc | $0 | – | -23,830 | -100.0% | -0.04% | – |
| PODD | Exit | Insulet Corp | $0 | – | -58,000 | -100.0% | -0.63% | – |
| UHS | Exit | Universal Health Services Inccl b | $0 | – | -25,800 | -100.0% | -0.66% | – |
| OMER | Exit | Omeros Corp | $0 | – | -237,453 | -100.0% | -1.00% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS INC | 36 | Q3 2023 | 19.7% |
| MASIMO CORP | 32 | Q3 2023 | 5.8% |
| LA JOLLA PHARMACEUTICAL CO | 31 | Q2 2022 | 9.7% |
| REGENXBIO INC | 30 | Q4 2022 | 10.8% |
| AGENUS INC | 29 | Q2 2022 | 9.0% |
| PTC THERAPEUTICS INC | 28 | Q3 2023 | 12.8% |
| DICERNA PHARMACEUTICALS INC | 28 | Q3 2021 | 10.8% |
| MIRATI THERAPEUTICS INC | 26 | Q3 2023 | 6.2% |
| ARGENX SE | 26 | Q3 2023 | 5.3% |
| VERICEL CORP | 24 | Q3 2023 | 3.9% |
View RTW INVESTMENTS, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. | September 19, 2023 | 18,188,457 | - |
| ALLURION TECHNOLOGIES, INC. | August 11, 2023 | 3,457,707 | 7.4% |
| Orchestra BioMed Holdings, Inc. | May 05, 2023 | 5,620,645 | 15.7% |
| Renovacor, Inc.Sold out | April 05, 2023 | 0 | - |
| Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Aptevo Therapeutics Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| ASLAN Pharmaceuticals LtdSold out | February 14, 2023 | 0 | 0.0% |
| Athira Pharma, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| BELLUS Health Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Clearside Biomedical, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
View RTW INVESTMENTS, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13D/A | 2024-04-17 |
| SC 13D/A | 2024-03-01 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View RTW INVESTMENTS, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.